期刊文献+

TgAb水平预测TgAb阳性分化型甲状腺癌患者^(131)I治疗后病灶转移的价值分析

The value analysis of TgAb level in predicting metastasis of TgAb positive differentiated thyroid cancer after 1311 treatment
下载PDF
导出
摘要 目的观察抗甲状腺球蛋白抗体(TgAb)阳性分化型甲状腺癌(DTC)患者^(131)I治疗后血清TgAb水平的变化趋势,探讨TgAb水平变化对转移灶的预测价值。方法回顾性分析158例^(131)I治疗前TgAb阳性的DTC患者的临床资料,根据^(131)I治疗后随访1年时TgAb水平,分为TgAb转阴组和未转阴组,比较两组患者的病灶转移率,观察确诊转移与未转移患者的血清TgAb水平变化趋势。结果TgAb未转阴组的转移率明显高于TgAb转阴组,差异有统计学意义(P=0.002)。TgAb水平升高组与稳定组的转移发生率大致相仿,且高于TgAb水平下降组,但三组间差异无统计学意义(P=0.600)。进一步研究发现,19例确诊转移与139例未转移患者^(131)I治疗后血清TgAb水平变化趋势比较,差异有统计学意义(P=0.002)。结论当血清甲状腺球蛋白(Tg)阴性时,TgAb水平可作为TgAh阳性DTC患者^(131)I治疗后预测转移的监测指标。 Objective To observe the change trend of serum TgAb level in TgAb positive patients after ^(131)I treatment,and to explore the predictive value of TgAb level change in metastasis.Methods Clinical data of 158 cases of TgAb positive DTC patients admitted to our hospital before ^(131)I treatment were retrospectively analyzed.According to the TgAb level after ^(131)I treatment for 1 year,they were divided into the TgAb negative group and the TgAb non-negative group.At the same time,serum TgAb levels in patients with confimied metastasis and those without metastasis were observed.Results The metastatic rate of the TgAb non-negative group was significantly higher than that of the TgAb negative group,and the difference was statistically significant(P=0.002).The incidence of metastasis in the elevated TgAb group was roughly similar to that in the stable group,and higher than that in the decreased TgAb group,but there was no statistical significance between the three groups(P=0.600).Further study found that there was a statistically significant difference in the trend of serum TgAb level after ^(131)I treatment in 19 patients with confirmed metastasis and 139 patients without metastasis(P=0.002).Conclusion When serum Tg is negative,TgAb level can be used as a monitoring index to predict metastasis after 1,11 treatment in TgAb positive DTC patients.
作者 叶挺 易贺庆 李林法 Ye Ting
出处 《浙江临床医学》 2021年第10期1400-1402,共3页 Zhejiang Clinical Medical Journal
基金 国家卫生健康委员会与浙江省共建重点项目(WKJZJ-1814)。
关键词 分化型甲状腺癌 ^(131)I清甲治疗 甲状腺球蛋白 抗甲状腺球蛋白抗体 Differentiated thyroid cancer ^(131)I ablation therapy Thyroglohulin Anti-thyroglohulin antibody
  • 相关文献

参考文献2

二级参考文献24

  • 1National Cancer Institute. SEER cancer statistics factsheets: thyroid cancer [ R/OL ]. http : //seer. cancer, gov/staffacts/ html/thyro, html.
  • 2Rahmoun MN, Bendahmane 1. Anti-thyroglobulin antibodies in differentiated thyroid carcinoma patients : study of the clin- ical and biological, parameters [ J]. Ann Endocrinol ( Paris), 2014, 75(1):15-18.
  • 3Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thy- roglobulin autoantibodies : prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma [ J]. J Clin En- docrinol Metab, 1998, 83 (4) : 1121-1127.
  • 4Durante C, Tognini S, Montesano T, et al. Clinical aggres- siveness and long-term outcome in patients with papillary thy- roid cancer and circulating anti-thyroglobuhn autoantibodies [J]. Thyroid, 2014, 24(7):1139-1145.
  • 5Tsushima Y, Miyauchi A, ho Y, et al. Prognostic signifi- cance of changes in serum thyrogtobulin antibody levels of pre-and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients [ J ] Endocrine J, 2013, 60(7) :871-876.
  • 6Seo JH, Lee SW, Ahn BC, et al. Recurrerce detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody : special emphasis on using (18) F-FDG PET/CT [ J ]. Clin Endocrinol, 2010, 72 ( 4 ) : 558-563.
  • 7Smooke-Praw S, Ro K, Levin O, et al. Thyroglobulin anti- body levels do not predict disease status in papillary thyroid cancer [J]. Clin Endocrinol, 2014, 81(2):271-275.
  • 8Chiovato L, Latrofa F, Braverman LE, et al. 2003 Disap- pearance of humora! thyroid autoimmunity after complete re- moval of thyroid antigens [J]. Ann Intern Med, 2014, 139 (5 Pt i) :346-351.
  • 9Cooper DS, Doherty GM, Haugen BR, et al. American Thy- roid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Revised Ameri- can Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer [ J ]. Thyroid, 2009, 19(11) :1167-1214.
  • 10Sabra MM, Dominguez JM, Grewal RK, et al. Clinical out- comes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases [J]. J Clin Endocri- nd Metab, 2013, 98(5) :Eg29-E836.

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部